US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

45.97

+0.26860.59%

Post-market: 45.970.00000.00%16:15 EDT

Volume:2K

Turnover:106.96K

Market Cap:126.73M

PE:- -

High:46.65

Open:46.65

Low:45.51

Close:45.70

52wk High:48.78

52wk Low:27.68

Shares:2.76M

Float Shares:2.76M

Volume Ratio:0.85

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Spyre Therapeutics - Spy072 Well Tolerated with Adverse Event Rates Comparable to Placebo

THOMSON REUTERS

Spyre Therapeutics Inc: Spy072 in Combination with Il17-a/F in Hidradenitis Suppurativa (Hs) in Late 2027 or Early 2028

THOMSON REUTERS

Spyre Therapeutics - Topline Data for Spy072 in Psa and Axspa Expected Q4 2026

THOMSON REUTERS

Spyre Therapeutics Inc - Magnitude of Effect Did not Meet Company's Target to Prioritize Monotherapy Development of Spy072 in Rheumatoid Arthritis

THOMSON REUTERS

Spyre Therapeutics - Spy072 Shows Statistically Significant Benefits Versus Placebo on Multiple Endpoints

THOMSON REUTERS

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

Circio bolsters board as it advances circular RNA gene therapy platform

BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA

Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares

Guardant Health to Appeal Delaware Court Ruling in Patent Dispute; Shares Fall

MT Newswires Live

Guardant Health to appeal federal district court judgment in TwinStrand case

Guardant Health, Inc.: Remains Confident That it Did not Infringe Asserted Patents

THOMSON REUTERS

Guardant Health, - Current Guardant Reveal and Shield Products Excluded from Final Court Order

THOMSON REUTERS

Guardant Health to Appeal Federal District Court Judgment

THOMSON REUTERS

U.S. Court Orders Guardant to Pay $245 Million in DNA Sequencing Patent Dispute

Renalytix Discloses Director’s Link to Trellus Administration as KidneyIntelX Rollout Advances

Sector Update: Healthcare

MT Newswires Live

Guardant Health Loses $245.2 Million Patent Infringement Case

MT Newswires Live

Regenxbio reports FDA placed clinical hold on RGX-121

Twinstrand: Court Awards Co and Uw over $245.2 Mln in Damages, Accrued Royalties & Interest for Infringement That Occurred Through May 31, 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/LFSC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":45.9664,"timestamp":1788379200000,"preClose":45.6978,"halted":0,"volume":2330,"hourTrading":{"tag":"盘后","latestPrice":45.9664,"preClose":45.9664,"latestTime":"16:15 EDT","volume":10,"amount":459.664,"timestamp":1788380100277,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.005877744661668598,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"Post-Mkt","change":0.2686,"latestTime":"09-02 19:34:32 EDT","open":46.65,"high":46.65,"low":45.51,"amount":106959,"amplitude":0.024946,"askPrice":68.32,"askSize":100,"bidPrice":45.14,"bidSize":11,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":45.6978,"sharesOutstanding":2657035,"nav":45.8,"aum":126272203,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":45.9664,"preClose":45.9664,"latestTime":"16:15 EDT","volume":10,"amount":459.664,"timestamp":1788380100277,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.854983},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.854983,"shares":2757035,"dividePrice":0,"high":46.65,"amplitude":0.024946,"preClose":45.6978,"low":45.51,"week52Low":27.6794,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":45.9664,"committee":-0.801802,"eps":0,"divideRate":0,"volume":2330,"delay":0,"ttmEps":0,"open":46.65,"prevYearClose":36.6147,"prevWeekClose":45.9566,"prevMonthClose":45.79,"prevQuarterClose":45.2033,"fiveDayClose":47.5848,"twentyDayClose":47.4383,"sixtyDayClose":37.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662754989","title":"Spyre Therapeutics - Spy072 Well Tolerated with Adverse Event Rates Comparable to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662754989?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","SYRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662754982","title":"Spyre Therapeutics Inc: Spy072 in Combination with Il17-a/F in Hidradenitis Suppurativa (Hs) in Late 2027 or Early 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2662754982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662754982?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662549867","title":"Spyre Therapeutics - Topline Data for Spy072 in Psa and Axspa Expected Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662549867","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662549867?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662549807","title":"Spyre Therapeutics Inc - Magnitude of Effect Did not Meet Company's Target to Prioritize Monotherapy Development of Spy072 in Rheumatoid Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2662549807","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662549807?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662475498","title":"Spyre Therapeutics - Spy072 Shows Statistically Significant Benefits Versus Placebo on Multiple Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2662475498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662475498?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nTUA3HCVK8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LFSC","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662175441","title":"Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072","url":"https://stock-news.laohu8.com/highlight/detail?id=2662175441","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662175441?lang=en_us&edition=fundamental","pubTime":"2026-08-26 04:01","pubTimestamp":1787688060,"startTime":"0","endTime":"0","summary":"Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/25/3350866/0/en/spyre-therapeutics-announces-topline-results-from-the-rheumatoid-arthritis-sub-study-of-the-skyway-phase-2-trial-of-spy072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","SYRE","BK4007","RA","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662759663","title":"Circio bolsters board as it advances circular RNA gene therapy platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2662759663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662759663?lang=en_us&edition=fundamental","pubTime":"2026-08-26 01:07","pubTimestamp":1787677640,"startTime":"0","endTime":"0","summary":"Targovax ASA ( ($GB:0RIS) ) has issued an announcement. Circio Holding ASA has strengthened its board of directors as it enters a new development p...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/circio-bolsters-board-as-it-advances-circular-rna-gene-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/circio-bolsters-board-as-it-advances-circular-rna-gene-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNA","BK4585","FBT","SYNB","GNOM","IE0009354923.USD","LFSC","IBBQ","BK4139","IBB","BK4505","TBXU","CNCR","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662530687","title":"BeOne announces FDA approval for Tevimbra-based reginmen for HER2+ GEA","url":"https://stock-news.laohu8.com/highlight/detail?id=2662530687","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662530687?lang=en_us&edition=fundamental","pubTime":"2026-08-25 22:45","pubTimestamp":1787669120,"startTime":"0","endTime":"0","summary":"BeOne Medicines (ONC) announced that the U.S. FDA has approved the supplemental Biologics License Application for TEVIMBRA in combination with ZIIH...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beone-announces-fda-approval-for-tevimbra-based-reginmen-for-her2-gea-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBP","GDOC","IDNA","GNMX","IEIH","MRNY","BK4526","BMED","NVIB","LABU","ONC","XLVX","PINK","MEDI","MRNX","BK4588","BK4585","TBXU","BK4139","FRTY","TECB","IYH","SYNB","LFSC","PSCH","IBB","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662020952","title":"Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2662020952","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662020952?lang=en_us&edition=fundamental","pubTime":"2026-08-25 05:22","pubTimestamp":1787606549,"startTime":"0","endTime":"0","summary":"Guardant Health Co-CEO AmirAli Talasaz disposes of USD 6.35 million in common sharesGuardant Health Co-CEO AmirAli Talasaz sold 37,500 common shares on Aug. 21, 2026 through the Talasaz Family Foundat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL9NSL6W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Co-CEO AmirAli Talasaz Disposes of USD 6.35 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4588","FFOX","EKG","HELX","GNMX","BK4535","LFSC","GDOC","GNOM","LU0109394709.USD","LU0889565916.HKD","BK4551","LU0320765992.SGD","BK4196","PTH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662205974","title":"Guardant Health to Appeal Delaware Court Ruling in Patent Dispute; Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2662205974","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662205974?lang=en_us&edition=fundamental","pubTime":"2026-08-25 03:41","pubTimestamp":1787600471,"startTime":"0","endTime":"0","summary":"Guardant Health  said Monday it will appeal the final judgment of a Delaware district court related to a patent infringement dispute with TwinStrand Biosciences and University of Washington.The company said execution of the court's final decision and collection of potential royalties are on hold, pending the appeal.The potential royalties do not apply to the company's current versions of Guardant Reveal and Shield, which feature updated technology. Additionally, the company has made design improvements to Guardant360 that would exclude the impact of potential ongoing royalties.The patents have also been preliminarily invalidated in separate challenges before the US Patent and Trademark Office, the company added.Shares fell around 3.5% in late afternoon trading.Price: 164.62, Change: -6.07, Percent Change: -3.56","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","GNMX","HELX","LFSC","BK4551","FFOX","GH","LU0109394709.USD","PTH","BK4196","BK4588","EKG","LU0889565916.HKD","BK4535","GDOC","LU0320765992.SGD","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662030912","title":"Guardant Health to appeal federal district court judgment in TwinStrand case","url":"https://stock-news.laohu8.com/highlight/detail?id=2662030912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662030912?lang=en_us&edition=fundamental","pubTime":"2026-08-25 02:55","pubTimestamp":1787597714,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-to-appeal-federal-district-court-judgment-in-twinstrand-case-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-to-appeal-federal-district-court-judgment-in-twinstrand-case-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","BK4535","BK4551","GNMX","LFSC","BK4585","BK4196","BK4588","GDOC","PTH","GH","GNOM","LU0320765992.SGD","HELX","FFOX","EKG","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203463","title":"Guardant Health, Inc.: Remains Confident That it Did not Infringe Asserted Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203463","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662203463?lang=en_us&edition=fundamental","pubTime":"2026-08-25 02:44","pubTimestamp":1787597047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0L4:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","HELX","BK4588","BK4585","EKG","PTH","FFOX","GDOC","LU0109394709.USD","LU0320765992.SGD","LFSC","BK4551","GNMX","BK4535","LU0889565916.HKD","GNOM","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662203434","title":"Guardant Health, - Current Guardant Reveal and Shield Products Excluded from Final Court Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2662203434","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662203434?lang=en_us&edition=fundamental","pubTime":"2026-08-25 02:44","pubTimestamp":1787597047,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0L4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0889565916.HKD","LFSC","LU0320765992.SGD","GH","BK4551","HELX","GDOC","GNMX","GNOM","PTH","BK4585","FFOX","BK4588","EKG","BK4196","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034312","title":"Guardant Health to Appeal Federal District Court Judgment","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662034312?lang=en_us&edition=fundamental","pubTime":"2026-08-25 02:44","pubTimestamp":1787597047,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nFWN44L0L4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GDOC","LFSC","GNMX","LU0320765992.SGD","BK4588","PTH","HELX","LU0109394709.USD","BK4585","BK4196","BK4535","BK4551","LU0889565916.HKD","GNOM","FFOX","EKG","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662520885","title":"U.S. Court Orders Guardant to Pay $245 Million in DNA Sequencing Patent Dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2662520885","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662520885?lang=en_us&edition=fundamental","pubTime":"2026-08-25 00:55","pubTimestamp":1787590534,"startTime":"0","endTime":"0","summary":"UPDATE 2-U.S. court orders Guardant to pay $245 million in DNA sequencing patent disputeAug 24 (Reuters)-A U.S. court has ordered Guardant Health to pay more than $245.2 million to TwinStrand Bioscien","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL4N44L18D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU0320765992.SGD","EKG","LU0889565916.HKD","PTH","LFSC","FFOX","HELX","BK4535","BK4588","BK4196","GH","BK4585","GNOM","BK4232","BK4022","SAIA","BK4551","LU0109394709.USD","GDOC","GNMX","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661271017","title":"Renalytix Discloses Director’s Link to Trellus Administration as KidneyIntelX Rollout Advances","url":"https://stock-news.laohu8.com/highlight/detail?id=2661271017","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661271017?lang=en_us&edition=fundamental","pubTime":"2026-08-24 21:42","pubTimestamp":1787578963,"startTime":"0","endTime":"0","summary":"Renalytix ( ($GB:RENX) ) has issued an update. Renalytix plc, a London- and New York-based precision medicine diagnostics group, specializes in art...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/renalytix-discloses-directors-link-to-trellus-administration-as-kidneyintelx-rollout-advances?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/renalytix-discloses-directors-link-to-trellus-administration-as-kidneyintelx-rollout-advances?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FDIF","BMED","HTEC","GNMX","WDNA","BK4588","TMAT","PBE","IDNA","MEDX","SYNB","HELX","JDOC","GNOM","GDOC","XT","IBB","LFSC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279439","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279439?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:58","pubTimestamp":1787576324,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF  0.4% higher and the iShares Biotechnology ETF  down 0.2%,Guardant Health  lost a $245.2 million patent infringement lawsuit filed by TwinStrand Biosciences and the University of Washington, TwinStrand said. Guardant Health stock was down more than 1% premarket.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1883839398.USD","LU0029874061.USD","BK4585","BK4535","LU0128526141.USD","BK4588","IE00B64PRP62.GBP","GH","LFSC","HCSG","EKG","BK4550","XLV","GNMX","LU0061475181.USD","IE00B3QW5Z07.USD","HELX","BK4581","LABU","IE00BGHQF748.EUR","LU1894683348.USD","LU0320765992.SGD","IBB","BK4551","BK4137","FDN","FFOX","IE0034235188.USD","BK4196","GNOM","XBI","LU1894683264.USD","LU0889565916.HKD","PTH","BK4135","STT","GDOC","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661752702","title":"Guardant Health Loses $245.2 Million Patent Infringement Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2661752702","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661752702?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:51","pubTimestamp":1787572313,"startTime":"0","endTime":"0","summary":"Guardant Health  lost a $245.2 million patent infringement lawsuit filed by TwinStrand Biosciences and the University of Washington, TwinStrand said Monday.The final judgment, issued Friday, maintains a November 2023 jury verdict finding that Guardant Health willfully infringed two patents underlying TwinStrand's Duplex Sequencing technology in 11 royalty-bearing products and services, and awards TwinStrand and the University of Washington damages, accrued royalties and interest for infringement through May 31, 2026, the company said.The court ordered Guardant Health to pay a 6% royalty on sales of the covered products and services from June 1, 2026 until the expiration of the patents on March 15, 2033, the company said.Guardant is also required to provide quarterly accounting of US sales of the covered products and services, TwinStrand said.Guardant did not iimmediately reply to MT Newswires' request for comment.Shares of Guardant were down 1.6% in recent premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","LFSC","GH","PTH","LU0320765992.SGD","FFOX","LU0889565916.HKD","GNMX","BK4551","BK4196","EKG","GDOC","HELX","GNOM","BK4535","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661627309","title":"Regenxbio reports FDA placed clinical hold on RGX-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627309","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627309?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:20","pubTimestamp":1787570406,"startTime":"0","endTime":"0","summary":"Regenxbio (RGNX) provided an update on its investigational gene therapy, RGX-121, for the treatment of Mucopolysaccharidosis type II, also known as...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-fda-placed-clinical-hold-on-rgx-121-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-fda-placed-clinical-hold-on-rgx-121-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LFSC","IBBQ","FBT","BK4505","BK4563","TBXU","GNOM","BK4139","CNCR","IBB","BK4588","SYNB","RGNX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661727387","title":"Twinstrand: Court Awards Co and Uw over $245.2 Mln in Damages, Accrued Royalties & Interest for Infringement That Occurred Through May 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661727387","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661727387?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nP8N3M60G7:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","BK4535","BK4551","GNMX","LFSC","BK4585","BK4196","BK4588","GDOC","PTH","GH","GNOM","LU0320765992.SGD","HELX","FFOX","EKG","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}